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INTRODUCTION  
Rheumatoid arthritis (RA) is the most common inflammatory 
arthritis, affecting 0.5% to 1% of the general population worldwide. 
Although the prevalence is constant across the globe, regardless of 
geographic location and race, there are some exceptions. In China, the 
occurrence of RA is lower (about 0.3%), whereas it is substantially higher 
in other populations, such as the Pima Indians in North America (about 
5%). Because of its prevalence and the ready accessibility of joint 
samples for laboratory investigation, RA has served as a useful model for 
the study of many inflammatory and immune-mediated diseases
1
. As 
such, the information gleaned from these studies has provided new and 
unique insights into the mechanisms of normal immunity. 
Although RA is properly considered a disease of the joints, 
abnormal immune responses can cause a variety of extra-articular 
manifestations. In some cases, production of rheumatoid factor (RF) with 
the formation of immune complexes that fix complement contributes to 
extra-articular findings. RA is a systemic disease with a variety of extra-
articular manifestations. It is estimated that as many as 40% of patients 
may have extra-articular manifestations and in 15% these are severe. 
On occasion, extra-articular manifestations may be the major 
evidence of disease activity and source of morbidity and require 
management per se
2
.Although the frequency of patients with severe extra-
articular manifestations appears to be declining, these patients have an 
increased mortality compared to other persons with RA or age- matched 
normal controls. 
Some of the notable extraarticular manifestations are: 
1. Rheumatoid vasculitis 
2. Pleuropulmonary manifestations 
3. Cardiovascular disease 
4. Neurologic manifestations 
5. Eye involvement in the form of episcleritis and scleritis 
6. Sjogren‟s syndrome  
7. Felty‟s syndrome 
8. Osteoporosis 
9. Development of Lymphomas 
From 15 – 20% of patients with RA may develop Sjogren‟s syndrome 
with attendant keratoconjunctivitis sicca
2
. 
This study was undertaken to screen rheumatoid arthritis patients for 
the presence of sicca symptoms, look for objective evidence of sicca and 
estimate the prevalence of sicca syndrome in these patients. 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE  
RHEUMATOID ARTHRITIS: 
INTRODUCTION: 
Rheumatoid arthritis is a symmetric inflammatory arthritis that 
mainly affects the small joints of the hands and feet. Larger joints can be 
involved, usually in a symmetric fashion. 
Cartilage destruction and bone erosions are common, especially in 
rheumatoid factor–positive or anticitrullinated protein antibody–positive 
patients. 
Uncontrolled synovitis can lead to severe deformities, loss of 
function, and increased mortality. 
Early aggressive therapy seems to improve long-term outcomes in 
rheumatoid arthritis. 
Systemic manifestations include pulmonary disease, vasculitis, 
nodules, and eye disease. 
EPIDEMIOLOGY AND BURDEN OF THE DISEASE 
In past years, most investigators accepted a prevalence of 
rheumatoid arthritis (RA) in most populations of around 1%, with an 
incidence in women twice that in men. This number was based on many 
studies of population samples that varied among the surveys from 0.3% to 
1.5%
 
 
3-5
. This figure of 1% prevalence of RA in most populations may be 
changing, however, as incidence rates in different decades are studied. 
 
CLINICAL SYNDROMES OF EARLY RHEUMATOID ARTHRITIS: 
There are distinctive patterns of onset of rheumatoid arthritis. They are 
1. Insidious onset 
2. Acute or intermediate onset 
Insidious Onset 
RA has an insidious, slow onset over weeks to months in 55% to 
65% of cases
6
. The initial symptoms may be systemic or articular. In 
some individuals, fatigue, malaise, swollen hands, and diffuse 
musculoskeletal pain may be the first nonspecific complaints, with joints 
becoming involved later. 
Morning stiffness is a cardinal sign of inflammatory arthritis that 
can appear even before pain and may be related to the accumulation of 
edema fluid within inflamed tissues during sleep. The morning stiffness 
dissipates as edema and products of inflammation are absorbed by 
lymphatics and venules and returned to the circulation by motion 
accompanying the use of muscles and joints. To be specific for joint 
inflammation, morning stiffness (e.g., “difficulty moving around”) should 
persist for at least 30 to 45 minutes before disappearing. A similar “gel” 
phenomenon can occur if a patient is inactive for a period during the day. 
Acute or intermediate onset: 
Of patients, 8% to 15% have an acute onset of symptoms that peak 
within a few days. Rarely, a patient can pinpoint the onset of symptoms to 
a specific time or activity. 
SIGNS AND SYMPTOMS OF THE DISEASE: 
Articular Involvement  
The joints most commonly involved first in RA are the 
metacarpophalangeal (MCP) joints, proximal interphalangeal (PIP) joints, 
metatarsophalangeal joints, and wrists ( Table 1 )
7
 . Larger joints 
generally become symptomatic after small joints. 
 
 
Table -1   -- Distribution of Joints Involved in Attacks Based on a 
Cumulative Experience with 227 Patients
1 
Joint Involvement % Patients (Mean) % Patients (Range) 
MCP, PIP 91 74-100 
Wrists 78 54-82 
Knees 64 41-94 
Shoulders 65 33-75 
Ankles 50 10-67 
Feet 43 15-73 
Elbows 38 13-60 
Hips 17 0-40 
Temporomandibular 8 0-28 
Spine 4 0-11 
Sternoclavicular 2 0-6 
Para-articular sites 27 20-29 
 
 
Pain, swelling and tenderness may initially be poorly localized to 
the joints. Pain in affected joints, aggravated by movements is the most 
common manifestation of rheumatoid arthritis. Morning stiffness of more 
than 1 hour duration is an almost invariable feature of inflammatory 
arthritis. 
With persistent inflammation, a variety of characteristic joint 
changes develop. These can be attributed to a number of pathologic 
events, including laxity of supporting soft tissue structures; damage or 
weakening of ligaments , tendons and the joint capsule; cartilage 
degradation: muscle imbalance; and unopposed physical forces associated 
with the use of affected joints. Characteristic changes of the hand include 
(1) radial deviation of the wrist with ulnar deviation of the digits (“Z” 
deformity);(2)Hyperextension of the proximal interphalangeal joints with 
compensatory flexion of the distal interphalangeal joints.(swan-neck 
deformity);(3)flexion contracture of the proximal interphalangeal joint 
and extension of the distal interphalangeal joints (boutonniere deformity) 
In the foot, hallux valgus , widening of the forefoot, lateral 
deviation and dorsal subluxation of the toes can occur. 
 
DEFORMITIES OF THE HAND AND FINGERS IN  
RHEUMATOID ARTHRITIS 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Extra-articular Complications of Rheumatoid Arthritis  
Generally, the number and severity of extra-articular features vary 
with the duration and severity of the disease. Several of these features 
may be related to extra-articular foci of an immune response
8
. These 
patients with systemic immune responses have true rheumatoid disease, 
not just RA. Other unusual proteins and protein complexes in the 
circulation of patients with active rheumatoid disease include 
antiphospholipid antibodies, circulating immune complexes, and 
cryoglobulins. Extra-articular manifestations of RA are associated with 
excess mortality.
9 
SKELETON  
The skeleton has two anatomically and functionally separate 
components, cortical and trabecular bone, which respond differently to 
systemic and local diseases and to drugs. RA can be associated with 
generalized osteopenia and osteoporosis owing to the effects of drugs 
(especially corticosteroids). The risk of hip fracture and vertebral 
compression fracture can be quite high. Bone densitometry should be 
performed routinely in patients with RA, and treatment with 
bisphosphonates should be considered as an adjunct to therapy. 
MUSCLE  
Clinical weakness is common in RA, but is it caused by muscle 
involvement in the rheumatoid inflammation, or is it a reflex weakness 
response to pain? Most rheumatoid patients have muscle weakness, but 
few have muscle tenderness or elevated muscle enzymes in the blood. 
More recent studies have pointed to at least five different types of 
muscle disease in RA, although clinically relevant active myositis is 
uncommon
10
:  
   1.     Diminution of muscle bulk with atrophy of type II fibers 
   
2.     Peripheral neuromyopathy, usually due to a mononeuritis 
multiplex 
   3.     Steroid myopathy 
   
4.     Active myositis and muscle necrosis with foci of endomysial 
mononuclear cell infiltration 
   
5.     Chronic myopathy resembling a dystrophic process, probably the 
end stage of inflammatory myositis 
 
 
SKIN  
The most frequently recognized skin lesion in RA is the rheumatoid 
nodule, but there are several other manifestations as well. “Senile” 
purpura resulting from skin atrophy and capillary fragility is especially 
common in patients treated with glucocorticoids. Palmar erythema is 
common, but Raynaud's syndrome is rare.  
EYE  
Virtually all ocular manifestations of RA can be considered 
complications of the disease. Keratoconjunctivitis sicca is a component of 
Sjögren's syndrome. More directly related to the rheumatoid process and 
seen in the synovium and within rheumatoid nodules are scleritis and 
episcleritis. The highly differentiated connective tissues in the eye make 
rheumatoid manifestations particularly interesting and, when they occur 
in aggressive form, very serious. 
The episclera of the eye is highly vascular compared with the dense 
sclera. Scleritis, episcleritis, or both occur in less than 1% of rheumatoid 
patients.  
 In episcleritis, the eye becomes red and, in contrast to 
conjunctivitis, results in no discharge other than tearing in response to the 
gritty discomfort. Loss of vision does not occur as a direct result of the 
episcleritis, but a keratitis or cataract developing secondarily can cause 
visual loss.  
Scleritis causes severe ocular pain and a dark red discoloration. No 
discharge is present. Depending on the intensity of the process, scleritis 
can be localized and superficial or generalized, with or without 
granulomatous resorption of the sclera down to the uveal layer; when this 
complication occurs, it is termed scleromalacia perforans. 
Patients with RA who have an associated keratoconjunctivitis sicca 
secondary to Sjögren's syndrome have pruritic and painful eyes, 
sometimes leading to chronic blepharitis. 
INFECTION  
The incidence of infections as a complication of RA has paralleled 
the use of glucocorticoids, biologics, and immunosuppressive agents. 
TNF blockers are especially noteworthy because they have been 
associated with reactivation of tuberculosis and other opportunistic 
infections such as histoplasmosis. Pulmonary infections, skin sepsis, and 
pyarthrosis are among the most common infections in RA.
 11,12 
CANCER  
There is an increased risk for malignancy in RA patients, with an 
increased risk for lymphoma in certain patient subsets. Interstitial fibrosis 
may be a risk factor for lung carcinoma, particularly of the 
bronchoalveolar variety.
13
 One exception is cancer of the gastrointestinal 
tract, for which there seems to be a reduced risk for RA patients.
14
 It is 
possible that nonsteroidal anti-inflammatory drugs (NSAIDs) lower the 
risk of this form of cancer, as supported by evidence that these drugs can 
diminish the occurrence and numbers of colonic polyps. 
RA patients are at a two to three times higher risk of Hodgkin's 
disease, non-Hodgkin's lymphoma, and leukemia than the normal 
population; this is independent of immunosuppressive therapy.  
HEMATOLOGIC ABNORMALITIES  
Most patients with RA have a mild normocytic normochromic 
anemia that correlates with ESR elevation and the activity of the disease. 
Anemia has mixed causes in RA. One deficiency may mask evidence of 
others. A useful guide is that three quarters of rheumatoid patients with 
anemia have the anemia of chronic disease, whereas one quarter respond 
to iron therapy. Patients in both groups may have superimposed vitamin 
B12 or folate deficiencies. 
RENAL DISEASE  
The kidney is rarely involved directly in RA, but often is 
compromised indirectly by therapy. Amyloidosis is an unusual 
complication of chronic RA. AA amyloidosis, along with vasculitis and 
sepsis, is one of the most important life-threatening complications of RA.  
PULMONARY DISEASE  
There are at least six forms of lung disease in RA, as follows:  
•     Pleural disease 
•     Interstitial fibrosis 
•     Nodular lung disease 
•     Bronchiolitis obliterans with organizing pneumonia 
•     Arteritis, with pulmonary hypertension 
 
CARDIAC COMPLICATIONS  
Cardiac disease in RA can take many forms. It has become apparent 
that the increased risk of premature death in RA is due largely to an 
increased incidence of cardiovascular disease, primarily myocardial 
infarction and congestive heart failure. Advances in echocardiography 
have made the diagnosis of pericarditis and endocardial inflammation 
easier and more specific. Myocardial biopsy through vascular catheters 
has facilitated diagnosis and classification of myocarditis. 
DIAGNOSIS  
Criteria to establish the diagnosis of RA are based on an effective 
clinical history and physical examination, laboratory tests, and exclusion 
of other diagnoses. No single feature or laboratory test is sufficient for a 
definite diagnosis. The 1988 American College of Rheumatology criteria 
for classification usually are not used in individual cases for diagnosis; 
however, the requirement that objective evidence for synovitis must be 
present for at least 6 weeks is an important one especially because many 
transient forms of synovitis are observed in primary care settings . 
 
 Table 2   -- 1988 Revised American Rheumatism Association Criteria 
for Classification of Rheumatoid Arthritis
1 
Criterion Definition 
1. Morning 
stiffness 
Morning stiffness in and around the joints lasting at 
least 1 hr before maximal improvement 
2. Arthritis of 
≥3 joint areas 
At least 3 joint areas simultaneously having soft tissue 
swelling or fluid (not bony overgrowth alone) observed 
by a physician (the 14 possible joint areas are [right or 
left] PIP, MCP, wrist, elbow, knee, ankle, and MTP 
joints) 
3. Arthritis of 
hand joints 
At least 1 joint area swollen as above in wrist, MCP, or 
PIP joint 
4. Symmetric 
arthritis 
Simultaneous involvement of the same joint areas (as in 
criterion 2) on both sides of the body (bilateral 
involvement of PIP, MCP, or MTP joints is acceptable 
without absolute symmetry) 
5. Rheumatoid Subcutaneous nodules over bony prominences or 
Criterion Definition 
nodules extensor surfaces, or in juxta-articular regions, observed 
by a physician 
6. Serum 
rheumatoid 
factor 
Demonstration of abnormal amounts of serum 
rheumatoid factor by any method that has been positive 
7. 
Radiographic 
changes 
Changes typical of RA on posteroanterior hand and 
wrist radiographs, which must include erosions or 
unequivocal bony decalcification localized to or most 
marked adjacent to the involved joints (osteoarthritis 
changes alone do not qualify) 
 
The history and physical examination are the most sensitive and 
specific tools for diagnosis of RA. Initial laboratory tests often show the 
results in the following list . 
•     Normal white blood cell count and differential 
•     Thrombocytosis 
•     Mild anemia (hemoglobin 10 g/dL), normochromic and either 
normocytic or microcytic 
•     Normal urinalysis 
•     ESR 30 mm/hr or greater and C-reactive protein level greater than 0.7 
pg/mL 
•     Normal renal, hepatic, and metabolic tests 
•     Normal serum uric acid level 
•     Positive RF test (about 70% to 80% of patients; present in many 
normal individuals, patients with other rheumatic diseases, and 
individuals with chronic infections) 
•  
   
Anticitrullinated protein antibody (about 80% to 90% of patients; can 
be seen in other diseases, including active tuberculosis) (especially 
useful in early synovitis) 
 
SJOGREN’S SYNDROME : 
In 1933, Sjögren described the association of filamentary keratitis 
with arthritis. Previously, in 1882, Leber had described filamentary 
keratitis, and in 1888, Mikulicz had described a patient with bilateral 
lacrimal and parotid gland enlargement. Biopsy of these glands revealed 
extensive round cell infiltration. In 1953, Morgan and Castleman
13
 noted 
the similarity between the glandular enlargement described by Mikulicz 
and the keratitis described by Sjogren. Subsequently, these disorders were 
considered to be variants of the same process, and the term Sjögren's 
syndrome (SS) became more widely used.
14 
DEFINITIONS : 
Primary SS is best defined as dry eyes and dry mouth secondary to 
autoimmune dysfunction of the exocrine glands. Secondary SS is the 
same disease in the presence of another autoimmune connective tissue 
disorder. Until relatively recently (1980), the terms sicca syndrome and 
sicca complex were used interchangeably with SS in the literature, and 
their routine use in clinical settings persists today. 
CAUSE AND PATHOGENESIS  
Animal models of SS have provided some important insights 
regarding the immunopathogenesis of this disease: (1) SS has a strong 
immunogenetic component, (2) the inflammatory infiltrate is largely T 
cell driven, (3) autoimmune sialadenitis can be triggered by viral 
infection, (4) relatively specific autoantibodies are produced, and (5) 
genes regulating apoptosis influence the chronicity of lymphocytic 
infiltration and are candidates for therapeutic manipulation. 
CLINICAL MANIFESTATIONS  
OCULAR  
Although the most prominent ocular manifestation of SS is dry eye, 
patients are often unaware of dryness as a presenting symptom. Instead, 
they may complain of a foreign body–type sensation manifested by 
scratchiness, grittiness, or irritation from a “grain of sand.” Other 
common symptoms of dry eye include photophobia, redness, and ocular 
fatigue. Thick mucous strands may cause blurring of vision, and the 
eyelids may be encrusted, especially on awakening. If the condition 
persists and is untreated, symptoms may reflect complications of 
xerophthalmia, including pain, intense photophobia indicative of corneal 
abrasion, and discharge, possibly indicative of infection. Infections 
threaten sight and are most often caused by gram-positive bacteria. 
 
 
ORAL  
In contrast to dry eye, patients often complain of a dry mouth. 
Physicians caring for SS patients are accustomed to seeing them carry 
plastic water bottles because they require a constant supply of moisture to 
be comfortable. The dry-mouth patient describes a parched feeling in the 
mouth, often extending to the throat. Eating is often difficult without 
supplemental liquids. Owing to a reduction in salivary volume and the 
subsequent loss of the antibacterial properties of saliva, tooth decay is 
accelerated. In fact, unexplained rampant dental caries may be the first 
sign of dry mouth. 
OTHER XEROSES  
Dry nose is common and may lead to inflammation with subsequent 
congestion, crusting, and epistaxis. Xerotrachea may result in a chronic 
dry cough. Dry skin may lead to pruritus and excoriation. Rarely, 
secondary infection may occur. Vaginal dryness may lead to pruritus, 
irritation, and dyspareunia. Although the most common cutaneous 
manifestation of SS is dryness, little is known about the precise cause or 
whether cutaneous dryness is truly part of the autoimmune exocrinopathy 
of SS. Sweat volume is reduced in SS patients,
15
 and a skin biopsy 
revealed lymphocytic infiltrates surrounding eccrine glands and ducts in 
one patient suffering from severe anhidrosis.
16 
Table 3 -- Systemic Manifestations Associated with Sjögren's 
Syndrome 
   
 Musculoskeletal  
    Arthralgias 
    Myalgias 
 
 
   
 Cutaneous  
    Dry skin 
    Hyperglobulinemic purpura 
    Vasculitis 
 
 
   
 Pulmonary  
    Xerotrachea 
    Pulmonary infiltrate 
    Micronodules 
 
 
   
 Gastrointestinal  
    Esophageal dysmotility 
    Pancreatitis 
    Hepatitis 
 
 
   
 Renal  
    Renal tubular acidosis 
    Interstitial nephritis 
 
 
   
 Neurologic  
    Peripheral neuropathy 
    Cranial neuropathy (especially fifth cranial nerve) 
    Central nervous system disease 
 
 
   
 Hematologic  
    Leukopenia 
    Anemia 
    Lymphoma 
 
 
 
SECONDARY SJÖGREN'S SYNDROME  
Although secondary SS is defined as xerostomia and xerophthalmia 
in the presence of an autoimmune connective tissue disease, it is 
important to note that secondary SS is not monolithic. In other words, the 
characteristics of SS may vary among the different connective tissue 
disorders. Additionally, SS is a common accompaniment of autoimmune 
disorders not generally considered to be connective tissue diseases, such 
as thyroiditis, primary biliary cirrhosis, and MS. Thus, signs of SS should 
not be overlooked in these contexts. 
Clinical SS affects approximately 20% of patients with RA. Thirty-
one percent have positive MSG biopsies.
17
 SS-A antibodies have been 
found in 4% to 23% of RA patients.
17,18,19
 These patients are more likely 
to have severe sicca complaints and positive MSG biopsies. 
CLINICAL OUTCOMES  
When followed over a 10-year period, approximately one third of 
patients with sicca complaints eventually fulfilled the criteria for SS.
 20,21
 
Development of disease and severity of sicca symptoms correlate with the 
presence of autoantibodies, particularly ANA and SS-A, and the serum 
IgG level. 
DIAGNOSIS AND WORKUP:  
The modalities used for the workup of SS are the basis for most of 
the criteria proposed for the classification of SS. Thus, the evaluation of a 
patient with suspected SS often requires cooperation among the 
rheumatologist, ophthalmologist, and dental specialist. The workup of SS 
is based on the American-European Consensus Group modification of the 
European Community criteria shown in Table 3. 
Table 4  -- AEC Criteria for Sjögren's Syndrome 
   I.     Symptoms of dry eye 
   
 Patients must have a positive response to at least one of the 
following:  
   
 Have you had daily, persistent, troublesome dry eyes for 
more than 3 months? 
   
 Do you have a recurrent sensation of sand or gravel in the 
eyes? 
    Do you use tear substitutes more than three times a day? 
 
 
   II.   Oral symptoms 
   
 Patients must have a positive response to at least one of the 
following:  
   
 Have you had a daily feeling of dry mouth for more than 3 
months? 
    Have you had recurrently or persistently swollen salivary 
glands as an adult? 
   
 Do you frequently drink liquids to aid in swallowing dry 
food? 
 
 
   III.   Ocular signs 
   
 Patients must have objective evidence of ocular involvement, 
defined as a positive result from at least one of the following two 
tests:  
    Schirmer test performed without anesthesia (5 mm in 5 min) 
   
 Rose bengal score or other ocular dye score (4 according to 
van Bijsterveld's scoring system) 
 
 
   IV.   Histopathology 
   
 This criterion is met if an expert histopathologist evaluates focal 
lymphocytic sialadenitis with a focus score of 1 in the patient's 
minor salivary glands (obtained through normal- appearing 
mucosa). The focus score is defined as the number of lymphocytic 
foci adjacent to normal-appearing mucous acini and containing 
more than 50 lymphocytes/4 mm
2
 of glandular tissue. 
 
  
V.  Salivary             
gland 
involvement   
 
   
               Patient must have objective evidence of 
salivary gland involvement, defined by a positive result 
for at least one of the following diagnostic tests:  
   
 Unstimulated whole salivary flow (1.5 ml in 15 
min) 
   
 Parotid sialography showing the presence of 
diffuse sialectasis (punctate, cavitary, or 
destructive pattern) without evidence of 
obstruction in the major ducts 
   
 Salivary scintigraphy showing delayed uptake, 
reduced concentration, delayed excretion of 
tracer, or some combination of these 
 
 
   VI.   Autoantibodies 
    Patient must have the following autoantibodies present in serum: 
antibodies to Ro (SS-A) or La (SS-B) 
 
Definite Sjögren's syndrome requires the presence of four criteria, one of 
which must be either a positive biopsy or autoantibodies 
Exclusions: prior head and neck radiation, hepatitis C infection, human 
immunodeficiency virus (HIV) or acquired immunodeficiency syndrome 
(AIDS), preexisting lymphoma, sarcoidosis, graft-versus-host disease, use 
of anticholinergic drugs 
 
Serologies, particularly ANA and SS-A and SS-B, correlate with 
focus score on biopsy.
22 
Serum IgG is the most specific predictor of a 
positive biopsy but has relatively low sensitivity.
23
A recent report of 41 
patients tested for the presence of anti–SS-A and anti–SS-B and 
undergoing MSG biopsy showed a fairly high negative predictive value of 
anti–SS-A for MSG biopsy.24 Anti–SS-B may be useful in identifying 
primary SS among patients presenting with xerostomia, xerophthalmia, 
and undifferentiated features of connective tissue disorder.
25
  
 
 
 
TREATMENT  
Therapy for SS has three phases. The first phase consists of external 
moisture replacement or capture. This approach can be applied to the oral 
cavity, eyes, nose, skin, and genital tract. The second phase consists of 
stimulation of endogenous secretions, which has proved effective mainly 
for xerostomia. This approach is currently under investigation for other 
xeroses, including the eyes and skin. Finally, patients with systemic 
manifestations, such as pulmonary disease, vasculitis and 
pseudolymphoma, may require corticosteriods, cytotoxic agents, or both. 
 
 
 
 
 
 
 
  
 
AIMS AND OBJECTIVES 
 
1. To evaluate the prevalence of the sicca syndrome in patients with 
rheumatoid  arthritis 
2. To estimate the prevalence of sicca symptoms in patients with 
rheumatoid arthritis and to look for correlation between the 
prevalence of sicca symptoms and disease duration and activity 
3. To look for the presence of the primary sicca syndrome using 
antibody assay in patients who have objective evidence of sicca 
symptoms.   
 
 
 
                    MATERIALS AND METHODS 
Ours was a cross sectional study carried out for a period of 1 year. 
The setting was the Department of Medicine, Government Rajaji 
Hospital, Madurai. Approval was obtained from the ethical committee 
headed by the Dean, Govt Rajaji Hospital.  Informed written consent was 
obtained from all patients. The study population consisted of patients 
attending the outpatient department of rheumatology who were randomly 
selected. The data obtained was analysed using EPI Info 2002 statistical 
software. 
   The study was carried out on 40 patients attending the 
Rheumatology out-patient department of Madurai Medical College with 
an established diagnosis of RA, as defined by the American College of 
Rheumatology 1987 criteria.  
   Patients were considered seropositive if the rheumatoid factor 
(Latex agglutination test) was positive (>8 IU/L) on atleast one occasion 
during the course of their disease. 
    All patients had been treated with nonsteroidal anti-inflammatory 
drugs (diclofenac, 100-150 mg/day) daily. Treatment with a DMARD was 
initiated when a diagnosis of RA was made. All the patients included in 
our study were receiving one or more DMARDs including chloroquine, 
sulfasalazine and methotrexate. Some of them were on low dose steroids 
(5-15mg/day) depending on severity of symptoms. 
INCLUSION CRITERIA : 
 Patients who satisfied the American College of Rheumatology 1987 
criteria. 
 Age group -  17 to 60 years irrespective of the sex 
 Any duration of illness 
EXCLUSION CRITERIA 
 Past head and neck irradiation treatment 
 Hepatitis C infection 
 AIDS 
 Pre-existing  lymphoma 
 Use of anti-cholinergic drugs 
A questionnaire prepared noted the duration of RA, duration of  
early morning joint stiffness, personal history including smoking, 
medications and occupation. The questionnaire also included questions on 
oral and ocular symptoms. The use of current and previous disease-
modifying drugs, corticosteroid use and analgesics was noted. Cigarette 
consumption was evaluated in pack years (1 pack yr = 20 cigarettes/day 
for 1 yr). 
  A detailed clinical examination consisting of  examination of the 
eyes and oral cavity ,salivary gland swelling, the number of tender 
and swollen joints and systemic examination was performed. All 
patients had venous blood taken for full blood count, renal function 
tests, erythrocyte sedimentation rate and immunological 
investigations including rheumatoid factor (latex agglutination test). 
 All patients were made to undergo Schirmer‟s I test using test strips 
and only those patients who had symptoms and objective evidence 
of dry eye in the form of wetting of the test strips less than or equal 
to 5 mm in 5 minutes were subjected to antibody assay.  
 The activity of the disease was assessed using DAS 28(Disease 
activity score).Disease activity score is a composite score using 
tender and swollen joint count, ESR and patients‟ global assessment 
activity using a 100 mm visual analogue scale. 
 DAS28 = 0.56 √(no.of tender joints) + 0.28 √(no.of swollen joints) 
+0.70 log(ESR)+0.014 (global assessment in mm). 
 
Classification 
 Mild   <3.2 
 Moderate  3.2-5.1 
 Severe  >5.1 ( Minimum score :0; Maximum score : 9 ) 
Parameters used in Disease activity score: 
(1) Total 28 joint count for tenderness 
(2) Total 28 joint for swelling 
(3) ESR in mm in first hour 
(4) Patient assessment of global health using a 100mm visual analogue 
scale ranging from 0(very good) to 100 (very poor ). 
 
                                          
 
 
Schirmer’s test and auto antibody profile : 
SCHIRMER – I TEST: 
The test was performed according to published guidelines. Patients 
had not used tear substitutes for atleast one hour before examination. 
Patients dried their eyes carefully with a soft paper tissue ; then the test 
strips – always starting with the right eye – were placed between the 
medial and lateral parts of the lower eyelid, and removed after five 
minutes. Anaesthesia was not used. A positive test for reduced tear 
production was recorded if the strips were wetted 5 mm or less in one or 
both eyes, starting from the notch of the test strip corresponding to the 
inferior lid margin. 
AUTO-ANTIBODY PROFILE: 
Those patients who had oral and ocular sicca symptoms and a 
positive Schirmer‟s test in one eye were subjected to a blood profile for 
extractable nuclear antigens. The test kit used consisted of test strips with 
six antigens namely RNP, Smith antigen ,SS-A native , Ro – 52 
recombinant , SS-B,Scl-70 , Jo-1 .  Following this, the revised criteria 
were applied to estimate the prevalence of the sicca syndrome.  
 
 
  
 
 
 
 
SCHIRMER’S TEST BEING PERFORMED ON A PATIENT 
 
 
 
 
 
 
 
 
 
 
 
 
 ENA REPORT OF PATIENT SHOWING NEGATIVE RESULTS FOR 
ALL SIX EXTRACTABLE  NUCLEAR ANTIGENS 
 
 ENA REPORT OF PATIENT SHOWING STRONG POSITIVITY FOR  
SS-A & Ro - 52  
 ENA REPORT OF PATIENT SHOWING BORDERLINE 
POSITIVITY FOR  Ro - 52  
 STATISTICS : 
Data analysis was done using epidemiological  information  
statistical software. Using the software, the frequencies, mean, standard 
deviation and  „p‟ values were calculated. Chi square test and one way 
ANOVA were applied to the quantitative variables. „p‟ value < 0.05 was 
taken as significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
Baseline demographics and clinical characteristics: 
The study was conducted from December 2010 to November 2011 
recruiting subjects from the rheumatology outpatient clinic of 
Government Rajaji Hospital, Madurai. A total of 40 RA patients were 
enrolled during this study period. Women outnumbered men in the study 
population with 32 women and 8 men. In our study, the age of the 
participants varied from 17  to 60 years. 
Table - 1 
AGE DISTRIBUTION: 
 
Age in years 
No.of 
males 
No.of  
Females 
Total 
15 – 25 0 0 0 
26 - 35 12 2 10 
36 – 45 9 3 6 
46 – 55 13 1 12 
> 55 6 2 4 
Total 40 8 32 
 
In our study, the age of the participants varied from 25 to 60 years. 
Age greater than 60 years was an exclusion criterion. 
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Table - 2 
SEX DISTRIBUTION 
 
Sex No.of cases 
Male 8 
Female 32 
 
Of the total 40 RA patients, 32 were women and 8 were men in a 
ratio of 4:1 
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Table – 3 
Duration of Illness 
 
Duration No.of cases 
<  1 year 6 
1 – 10 years 29 
11 – 20 years 4 
 > 20 years 1 
Total 40 
 
In our study, the duration of illness ranged from as short as 2 
months to as long as 22 years. The maximum number of patients were 
found to have an illness duration of  1- 10 years. 
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Table - 4 
PREVALENCE OF SICCA SYMPTOMS  
 
Sicca Symptoms No.of cases 
Dry Eye only 25 
Dry mouth only 7 
Both Dry eye and Dry 
mouth 
7 
 
Of the 40 patients, 25 patients had only symptoms of dry eye with a  
prevalence of 62.5 %. 7 patients (17.5%)  had only symptoms of dry 
mouth and 7(17.5%) patients had symptoms of both dry eyes and dry 
mouth. 
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Table – 5 
PREVALENCE OF OBJECTIVE EVIDENCE OF DECREASED 
TEAR PRODUCTION (POSITIVE SCHIRMER’S TEST) 
 
Schirmer‟s Test No.of cases Both Eyes  
< 5mm 
One eye 
< 5mm 
 <  5mm 13   (32.5%) 8 5 
> 5 mm 27  (67.5%)   
 
Of the 40 patients studied, 13(32.5%) patients had a positive 
Schirmer‟s test. Of these 8 patients were positive in both eyes and 5 were 
positive in one eye. 
 
 
 
 
 
 
  
 
Table – 6 
CORRELATION BETWEEN DRY EYE AND DISEASE 
DURATION: 
 
Duration No.of cases Dry Eye 
Yes 
Dry Eye 
No 
<  1 year 6 2 4 
1 – 10 years 29 19 10 
11 – 20 years 4 3 1 
 > 20 years 1 1 0 
Total 40 25 15 
 
There was no correlation between duration of illness and the 
occurrence of dry eye symptoms with a „p‟ value of 0.271. 
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 Table – 7 
CORRELATION BETWEEN DRY EYE AND DAS 28 
DAS 28 Total cases Dry Eye 
Yes 
Dry Eye 
No 
 <  3.2 2 1 1 
3.2 – 5.1 24 16 8 
> 5.1 14 8 6 
Total 40 25 15 
 
There was no correlation between disease severity assessed by DAS 
28 and occurrence of dry eye symptoms with a „p‟ value of 0.271. 
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 Table – 8 
CORRELATION BETWEEN DRY MOUTH AND DISEASE 
DURATION 
 
Duration of 
illness 
Total cases Dry Mouth 
Yes 
Dry Mouth 
No 
<  1 year 6 0 6 
1 – 10 years 29 3 26 
11 – 20 years 4 3 1 
 > 20 years 1 1 0 
Total 40 7 33 
 
There was no correlation between duration of disease and the 
occurrence of dry mouth symptoms with a „p‟  value of  0.4 
 
 
 
 
 
  
Table - 9 
CORRELATION  BETWEEN DRY MOUTH AND DAS 28: 
 
DAS 28 Total cases Dry Mouth 
Yes 
Dry Mouth 
No 
 <  3.2 2 1 1 
3.2 – 5.1 24 5 19 
> 5.1 14 2 12 
Total 40 8 32 
 
There was a positive correlation between disease severity  assessed 
by DAS 28 and the occurrence of dry mouth symptoms with a „p‟ value 
of 0.03. 
Only 2 of the 40 patients studied, satisfied the revised AEC criteria 
for the diagnosis of primary sicca syndrome by testing positive for either 
SS- A or SS- B yielding a prevalence rate of  5 %. 
 
 
DISCUSSION 
The prevalence of Sjogren‟ s syndrome in association with 
autoimmune disease is not well established. This results from the lack of 
uniform criteria for the diagnosis of this syndrome, differences in 
diagnostic techniques for evaluating keratoconjunctivitis sicca and 
xerostomia, and the absence of prospective studies on the true prevalence 
of the syndrome in association with other diseases. 
Sjogren‟s syndrome can be diagnosed when any two of the 
following three clinical features are present : dry eyes, dry mouth and 
arthritis. Typical lesions in the eyes and mouth, however, are not always 
present at the same time nor at the same stage of development ; also, 
spontaneous clinical remission may occur.  
 
Demographics and clinical characteristics : 
This was a cross- sectional study carried out on 40 RA patients of 
whom 32 were women and 8 were men. Duration of illness ranged from 
less than a year to as long as 22 years.The age of the patients ranged from 
25 – 60 years with an age > 60 years being an exclusion criterion for the 
study. 
Prevalence of sicca symptoms and objective evidence of decreased 
tear production: 
In our study , 62.5% of the 40 patients responded positively to 
questions on dry eye symptoms, 17.5% had symptoms of dry mouth, 
17.5% had symptoms of both dry eye and dry mouth. In a similar study 
done by T Uhlig et al
26
 , ocular sicca symptoms were reported in 38%, 
oral sicca symptoms in 50% and a combination of both in 27 %. Reduced 
tear production as evidenced by a positive Schirmer‟s test was present in 
29%. Of the 40 patients studied, 13 patients had a positive Schirmer‟s test 
with a prevalence of 32.5% closely paralleling the findings of the above 
mentioned study. Previous studies examining the sicca symptoms in RA 
patients are sparse. Andonopoulos et al
27
 examined 111 RA patients and 
found sicca symptoms from eyes in 38% , from mouth in 6%. In another 
minor study
28, Schirmer‟s test was reduced in 30% of RA patients 
mirroring the findings of our study. Such different results may be partly 
explained by different approaches in the assessment of sicca symptoms 
 
Correlation of sicca symptoms with disease activity and duration: 
Our study showed a lack of correlation between dry eye symptoms 
and disease duration. Likewise there was also no correlation between 
symptoms of dry eye and disease activity as assessed by DAS 28. In our 
study however, a positive correlation was found between symptoms of 
dry mouth and disease activity whereas no correlation could be made out 
between dry mouth symptoms and disease duration. These findings are 
similar to those of the study conducted by T Uhlig et al
26
 in which no 
correlation could be found between ocular and oral dryness and disease 
activity and duration. 
 
Prevalence of sicca syndrome in RA patients: 
The prevalence of sicca syndrome in our study as evidenced by 
patients satisfying the revised AEC criteria was 5%. In a study by Fujita 
et al
29
 of 72 Japanese patients, just 10% of them had secondary Sjogren‟s 
syndrome. The presence of sicca syndrome in RA has been found to be 
higher in other studies. Cimmino et al
30
 found it in 17.5% of Italian RA 
patients and Martinez Castro et al
31
 in 55% of Spanish RA population. 
This high variability from study to study may be due to the genetic 
background of the studied population and methods chosen to evaluate 
glandular dysfunction. 
 
 
According to the findings of our study and the above mentioned 
studies,rheumatologists and ophthalmologists should be aware of high 
indices of sicca symptoms in RA & seek for sicca syndrome 
independently of the activity and duration of  rheumatoid arthritis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
In conclusion, the prevalence of ocular sicca symptoms in RA 
patients attending the rheumatology outpatient clinic in Government 
Rajaji hospital was 62.5% and that of oral symptoms alone was 17.5%. A 
combination of both ocular and oral dryness was present in 17.5%. 
There was no significant correlation between disease duration and 
symptoms of dry eye in our study group. There was no statistically 
significant correlation between dry eye symptomatology and disease 
activity. Though no correlation could be found out between disease 
duration and dry mouth, there was a statistically significant correlation 
between dry mouth symptoms and disease activity. 
The patients who completely satisfied the AEC criteria for the 
diagnosis of primary sicca syndrome in our study population were 2 in 
number yielding a prevalence of primary sicca syndrome of 5% . 
This study highlights the need for close and continual follow up of 
all patients with rheumatoid arthritis with a thorough clinical history and 
examination supplemented by screening tests for ocular and oral dryness. 
If patients test positive in screening tests, more advanced and invasive 
tests like minor salivary gland biopsy and auto antibody assay can be 
done to establish a diagnosis of Sjogren‟s syndrome. Such patients should 
be closely observed by physicians for the development of lymphomas 
which are highly likely to occur in this subset of patients of RA with the 
sicca syndrome. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 SUMMARY  
 
The study “ Prevalence of sicca syndrome in patients with 
rheumatoid arthritis” is a cross- sectional study conducted on patients 
visiting the outpatient department of rheumatology, Government Rajaji 
hospital,Madurai.Forty patients with rheumatoid arthritis fulfilling the 
American Rheumatologists association criteria(1987) were included in the 
study.Inclusion and exclusion criteria were strictly followed. Selected 
patients underwent clinical and laboratory evaluation to assess the 
severity and activity of disease including Schirmer‟s test for ocular 
dryness .DAS 28 score was calculated as an indicator of disease severity. 
Statistical analysis showed no correlation between disease activity , 
disease duration and the occurrence of sicca syndrome which was found 
to be present in 5% of our study patients reiterating the findings of other 
similar studies. 
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 PROFORMA 
A STUDY ON THE PREVALENCE OF SICCA SYNDROME  IN PATIENTS WITH RHEUMATOID ARTHRITIS 
 
Name : 
Age :                                            Sex : 
Address :                                     Ph : 
 
CLINICAL FEATURES  
Duration of illness – 
Disease Activity –  
Sicca symptoms – 
Ocular symptoms –  
1. Have you had daily, persistent, troublesome dry eyes for more than 3 months? 
2. Do you have a recurrent sensation of sand or gravel in the eyes? 
3. Do you use tear substitutes more than three times a day? 
Oral  symptoms –  
1. Have you had a daily feeling of dry mouth for more than 3 months? 
2. Have you had recurrent or persistently swollen salivary glands as an adult? 
3. Do you frequently drink liquids to aid in swallowing dry foods?  
Negative history -  History of head and neck irradiation, usage of anticholinergics/TCA, Jaundice 
EXAMINATION – 
Oral cavity examination – 
Examination of eye – scleritis/ episcleritis 
Schirmer’s test -              <5mm         >5mm 
Examination of salivary glands –  
Lymphadenopathy – 
Examination of joints for swelling and tenderness 
LABORATORY INVESTIGATIONS  – 
Renal function test 
Liver function test 
Hb  
TC 
ESR 
Anti  HCV 
HIV 
Rheumatoid factor 
ENA profile – 
SSA          SSB         Rho 52 
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1 Thirumalaiselvi 40 
     
f 3 months  1/2 hr      No 
     
No 5.06 
     
No 
       
No 22.3 mg% 0.78 mg% 110 mg% 9.3 
2 Kaleeswari 28     f 2 years      No      No 
    
No 5.54 
    
Yes 
       
No 24.6 mg% 0.92 mg% 115 mg% 9.6 
3 Krishnaveni 58     f 2 years     No 
      
Yes 
     
No 4.89 
    
Yes 
       
Yes 26.2 mg% 0.89 mg% 77 mg% 6.9 
4 Arumugam 32 
    
m  1 year     No 
       
No 
     
No 4.12 
     
No 
        
No 18.6 mg% 0.63 mg% 160 mg% 11.9 
5 Surendiran 58 
   
m 3 years     No 
       
No 
     
No 3.95 
     
No 
        
No 19.0 mg% 1.2 mg% 86 mg% 12 
6 Murugan 33   m 2 years  1/4 hr 
        
No 
     
No 4.43 
     
Yes 
        
No 27 mg% 0.8 mg% 68 mg% 11 
7 Pushpam 56    f 1 year  1/2 hr 
       
Yes 
      
No 4.99 
     
Yes 
       
Yes 18 mg% 0.8 mg% 90 mg% 10 
8 Ramalakshmi 32    f 4 years 1/4 hr 
        
No 
      
No 3.38 
      
Yes 
       
Yes 24 mg% 0.89 mg% 157 mg% 11.7 
9 Dhanalakshmi 52    f 15 years 1/4 hr 
       
No 
     
No 5.96 
      
Yes 
      
Yes 24.2 mg% 0.88 mg% 113 mg% 10.4 
10 Thilagam 53    f 2 years 1/4 hr 
      
Yes 
     
No 6.78 
      
No 
       
No 24.3 mg% 0.81 mg% 105 mg% 11.6 
11 Anarkali 58    f 10 years 1/4 hr 
       
No 
     
No 6.46 
      
No 
       
No 24 mg% 0.89 mg% 187 mg% 9.4 
12 Arokiammal 54   f 17 years 1/4 hr 
       
No 
     
No 4.47 
       
No 
       
No 20 mg% 0.7 mg % 123 mg% 10 
13 Manimala 48   f 3 years 1/4 hr 
      
No 
     
No 5.28 
       
No 
      
No 21.1 mg% 0.7 mg % 114 mg% 12.7 
14 Ajanta 49    f 1 year  1/4 hr 
      
Yes    No 2.94 
      
No 
      
No 20 mg% 1.0 mg% 102 mg% 11.8 
15 Manimegalai 50    f  1 year  1/4 hr 
       
No 
    
No 4.9 
      
No 
      
No 26.4 mg% 0.82 mg% 122 mg% 10.2 
16 Amudha 36    f   5 years  1 hr 
       
No 
     
No 4.09 
     
No 
      
No 26.7 mg% 0.92 mg% 114 mg% 10.2 
17 Gunasekaran 58 
   
m   5 years  1 hr 
       
No 
    
No 5.35 
     
No 
      
No 27.2 mg% 0.96 mg% 148 mg% 9.2 
18 Lalitha Ganesan 39    f  10 years  1/2 hr 
       
No 
    
No 6.18 
     
No 
      
No 16 mg% 0.71 mg% 77 mg% 11 
19 Vasantha 50    f  2 years   1/4 hr 
      
Yes 
    
No 4.87 
     
Yes      No 24 mg% 0.6 mg% 117 mg% 12 
20 Chandra 47     f  20 years  1/2 hr 
      
No 
      
No 3.28 
      
Yes 
      
Yes 29 mg% 0.8 mg% 107 mg% 10.6 
21 Veerammal 47     f  3 years  1/2 hr 
       
No 
      
No 5.87 
      
No 
       
No 29.7 mg% 0.7 mg% 135 mg% 9.8 
22 Chellammal 50    f  2 years   No 
        
No 
       
No 4.68 
      
Yes 
       
No 20.3 mg% 0.7 mg% 114 mg% 12 
23 Rajeswari 25     f 
 2 
months  1/4 hr 
        
No 
       
No 4.78 
        
No 
        
No 19.8 mg% 0.6 mg% 105 mg% 11 
24 Jasmine 31 
     
f  1 year    No 
         
No 
       
No 5.09 
       
Yes 
        
No 23 mg% 0.8 mg% 95 mg % 11.1 
25 Jothi 45 
   
m 
 2 
months    No 
         
No 
       
No 4.11 
       
No 
       
No 24.5 mg% 0.76 mg% 108 mg% 10 
26 Saraswathy 38   f  1 year   1/4 hr 
         
No 
       
No 2.89 
       
No 
        
No 29 mg% 0.7 mg% 99 mg% 12 
27 Gomathy 54   f 10 years  1 hr 
         
No 
      
No 6.7 
      
No 
       
No 27.3 mg% 0.86 mg% 132 mg% 10.2 
28 Bakeeral Begum 56   f 22 years  1/2 hr 
        
Yes 
      
Yes 4.3 
      
Yes 
       
Yes 29 mg% 1.4 mg% 150 mg% 10.2 
29 
Uma 
Maheswari 36    f 
 5 
months     No 
       
No 
      
No 5.15 
       
No 
        
No 14.42 mg% 1.04 mg% 72 mg% 12 
30 Vazhivittan 47 
   
m 8 months     No 
      
No 
      
No 4.51 
      
Yes 
      
No 26.2 mg% 0.86 mg% 134 mg% 9.7 
31 Fathima Beevi 45    f 12 years      No      No 
     
Yes 5.13 
       
Yes 
      
Yes 27.3 mg% 0.92 mg% 124 mg% 10.7 
32 Jareena Begum 48    f 2.5 years      No      No 
     
Yes 5.8 
       
Yes 
       
No 24 mg% 0.9 mg% 130 mg% 9.2 
33 Mariappan 38   m 7  years     1/4 hr      No 
     
No 4.26 
       
No 
        
No 25 mg% 1.0 mg% 123 mg% 9.8 
34 Latha 34    f 3 years     1/4 hr      No 
     
No 5.48 
       
No 
        
No 30 mg% 0.6 mg% 118 mg% 10.7 
35 Kaliammal 27    f 2 years     1/2 hr      No 
     
No 4.21 
       
Yes 
         
No 29 mg% 0.8 mg% 143 mg% 12 
36 Chandran 43 
   
m 10 years       No 
      
No 
      
No 5.07 
        
No      No 34 mg% 1.2 mg% 118 mg% 10.8 
37 Durga 27     f 8 months   1/2 hr 
      
No 
      
No 4.56 
       
Yes 
      
No 32 mg% 0.9 mg% 104 mg% 12.4 
38 Chitra 32 
     
f 5 years 1/4 hr 
      
No 
       
No 4.37 
       
Yes 
       
No 24 mg% 0.6 mg% 97 mg% 9.4 
39 Chinnammal 28 
     
f 3.5 years      1 hr 
      
No 
       
No 3.84 
      
No 
       
No 28 mg% 0.6 mg% 130 mg% 11.2 
40 Pothumponnu 35 
     
f 2 years 1/2 hr 
       
No 
       
No 5.85 
     
Yes 
        
No 19 mg% 0.9 mg% 124 mg% 9.7 
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8000 62 
    24 
mm 
   20 
mm      -      -      - 
6400 50 
    < 
5mm 
  <5 
mm Positive Negative Positive 
8300 60    9 mm 
    12 
mm      -      -      - 
8500 15 
  < 5 
mm    7 mm Negative Negative Negative 
9500 8 15 mm 
   15 
mm        -      -      - 
11400 15 25 mm 
    20 
mm       -                   -      - 
9800 20 < 5mm < 5 mm Negative Negative Negative 
14500 10 15 mm 20 mm      -     -     - 
8500 55 < 5 mm < 5 mm Negative Negative 
 
Negative 
9800 20 21 mm 17 mm      -      -     - 
11800 70 
  < 5 
mm 7 mm Negative Negative Negative 
8700 10 15 mm 15 mm     -       -     - 
8900 8 < 5 mm < 5 mm Negative Negative Negative 
6700 8 10 mm 12 mm      -      -      - 
9200 55 20 mm 15 mm       -        -      - 
10200 45 20 mm 20 mm      -      -      - 
8800 55 
 < 5 
mm < 5 mm Negative Negative Negative 
7200 55  30 mm 28 mm     -      -      - 
5600 30 < 5 mm < 5 mm Negative Negative 
 
Negative 
4700 20 
  10 
mm  15 mm      -       -      - 
7000 45 20 mm 25 mm      -       -      - 
8300 25 < 5 mm  9 mm Negative Negative Negative 
15700 47 18 mm 25 mm     -      -      - 
6700 39 12 mm  12 mm     -      -      - 
9500 60 14 mm 12 mm      -      -      - 
7000 12 15 mm 12 mm     -       -       - 
10000 47 14 mm 12 mm      -     -     - 
14400 25 <5 mm < 5 mm Negative Negative Negative 
7400 30 15 mm 20 mm       -        -       - 
6700 40 10 mm 12 mm      -      -      - 
6900 75 < 5 mm < 5 mm Negative Negative Positive 
11100 40 10 mm  8 mm      -     -      - 
9800 26 < 5 mm 8 mm Negative Negative Negative 
10300 38 8 mm 10 mm      -        -      - 
12000 30 20 mm 16 mm      -          -      - 
8000 35 10 mm  12 mm      -        -     - 
6700 27 15 mm 14 mm      -       -     - 
4500 30 
 < 5 
mm 10 mm Negative Negative Negative 
8600 15  14 mm 12 mm      -      -      - 
13000 45 
  18 
mm 20 mm      -      -      - 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
